Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nolbaxol
- Development stage
- Unknown
- Lead developer
- Yung Shin Pharmaceutical Industry
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Nolbaxol is a brand name for docetaxel, an antineoplastic agent and taxane derivative. It functions as an antimicrotubular agent by binding to free tubulin, promoting the polymerization of tubulin into stable microtubules, and inhibiting microtubule disassembly. This action blocks cellular mitotic and interphase functions, ultimately inhibiting cell division. Developed and manufactured by Yung Shin Pharm. Ind. Co., Ltd., Nolbaxol is used in the treatment of various cancers, including breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
- Brand names
- Nolbaxol活克癌注射液
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Nolbaxol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nolbaxol.